Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years

Diamant Thaçi; Stefano Piaserico; Kristian Gaarn Du Jardin; Richard B. Warren

doi:10.1111/jdv.18783

Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years

Diamant Thaçi^*, Stefano Piaserico, Kristian Gaarn Du Jardin, Richard B. Warren

^*Corresponding author for this work

Institute of Inflammation Medicine

1 Citation (Scopus)

Original language	English
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	37
Issue number	4
Pages (from-to)	e501-e504
ISSN	0926-9959
DOIs	https://doi.org/10.1111/jdv.18783
Publication status	Published - 04.2023

Funding

We would like to thank Eva Mateu, PhD of TFS HealthScience for editorial assistance and writing support. Richard B. Warren is supported by the Manchester NIHR Biomedical Research Centre.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)
Centers: Center for Research on Inflammation of the Skin (CRIS)

DFG Research Classification Scheme

2.22-19 Dermatology

Access to Document

10.1111/jdv.18783

Cite this

@article{2ea5711d4ec34d91a522a33dc9dc0541,

title = "Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years",

author = "Diamant Tha{\c c}i and Stefano Piaserico and \{Gaarn Du Jardin\}, Kristian and Warren, \{Richard B.\}",

note = "Funding Information: We would like to thank Eva Mateu, PhD of TFS HealthScience for editorial assistance and writing support. Richard B. Warren is supported by the Manchester NIHR Biomedical Research Centre. ",

year = "2023",

month = apr,

doi = "10.1111/jdv.18783",

language = "English",

volume = "37",

pages = "e501--e504",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "John Wiley and Sons Inc",

number = "4",

}

Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years. / Thaçi, Diamant; Piaserico, Stefano; Gaarn Du Jardin, Kristian et al.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 37, No. 4, 04.2023, p. e501-e504.

Research output: Journal Articles › Letters › peer-review

TY - JOUR

T1 - Long-term stability of PASI <3 response to tildrakizumab

T2 - Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years

AU - Thaçi, Diamant

AU - Piaserico, Stefano

AU - Gaarn Du Jardin, Kristian

AU - Warren, Richard B.

N1 - Funding Information: We would like to thank Eva Mateu, PhD of TFS HealthScience for editorial assistance and writing support. Richard B. Warren is supported by the Manchester NIHR Biomedical Research Centre.

PY - 2023/4

Y1 - 2023/4

UR - https://www.scopus.com/pages/publications/85143432553

U2 - 10.1111/jdv.18783

DO - 10.1111/jdv.18783

M3 - Letters

C2 - 36433779

AN - SCOPUS:85143432553

SN - 0926-9959

VL - 37

SP - e501-e504

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 4

ER -

Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years

Funding

UN SDGs

Research Areas and Centers

DFG Research Classification Scheme

Access to Document

Other files and links

Cite this